Rat Small interfering RNA (siRNA) harnesses the RNA interference (RNAi) pathway to degrade target mRNA molecules, thereby reducing protein expression with high specificity and efficiency. These models are widely used to study human diseases such as diabetes, neurodegeneration, osteoarthritis, and reproductive disorders due to their physiological and genetic similarities.

Key Advantages and Applications of Rat siRNA

• Targeted Gene Knockdown in Rat Models:
  Enables functional genomics studies by silencing genes implicated in disease pathways, such as 14-3-3 epsilon in testicular germ cell apoptosis and Survivin in hepatic stellate cells, facilitating mechanistic insights into apoptosis and fibrosis.
• Therapeutic Potential in Disease Models:
  siRNA targeting PARP-1 delivered via chitosan nanoparticles has been shown to alleviate diabetic peripheral neuropathy in streptozotocin-induced diabetic rats, demonstrating neuroprotection through reduced oxidative stress and inflammation.
• Innovative Delivery Systems:
  Advanced carriers like lipid nanoparticles and hydrogels improve siRNA stability, cellular uptake, and sustained release, as seen in rat models of osteoarthritis and intervertebral disc degeneration, enhancing therapeutic efficacy.
• Versatile Research Utility:
  Rat siRNA facilitates exploration of molecular mechanisms in various tissues, including cartilage, nerve, and liver cells, supporting drug discovery and validation of novel therapeutic targets.
• Custom Design and Validation:
  High-quality rat siRNA reagents undergo rigorous validation to ensure potent gene silencing with minimal off-target effects, critical for reproducible and reliable experimental outcomes.